The Economics of a Physician Practice Transaction: For most OB/GYN practice owners, a transaction with a PE-backed platform or strategic buyer will be the largest single financial event of their professional lives. Understanding the components of a transaction structure, how the purchase price is allocated across different consideration types, what obligations and opportunities each component entails, and how the total economic value of a deal should be evaluated is fundamental to making an informed decision. No two transactions are identical, but the key structural elements are consistent.
Cash at Close: The Liquidity Event
Cash at close refers to the immediate, lump-sum payment the seller receives at the closing of the transaction. In most physician practice PE transactions, this represents the largest single component of consideration, typically between 51% and 80% of the total enterprise value, depending on the deal structure and the buyer’s expectations for physician equity participation. Cash at close proceeds from the sale of a practice are generally eligible for long-term capital gains tax treatment when structured as a sale of equity or goodwill, which significantly enhances their after-tax value relative to ordinary income. Maximizing cash at close is typically a priority for physicians nearing retirement or with limited post-close investment flexibility.
Rollover Equity: The Second Bite
Rollover equity is the portion of enterprise value that sellers retain as an ownership stake in the combined, PE-backed entity rather than receiving as immediate cash. In a typical majority recapitalization, sellers roll over 20% to 49% of their transaction value into the new platform. This equity is generally held until the PE sponsor exits its investment, typically in 3 to 7 years, at which point sellers receive their proportional share of the exit proceeds. If the PE sponsor has successfully grown the platform’s EBITDA and achieved multiple expansion, the rollover equity can generate returns that substantially exceed the original investment. For example, rolling $3 million of proceeds into a platform that subsequently sells for a 2x equity return would generate $6 million in rollover proceeds, a highly meaningful “second bite of the apple.” The risk, of course, is that rollover equity is illiquid until the platform exit, and returns are not guaranteed.
Earnouts: Bridge the Gap, Accept the Risk
Earnout provisions are contingent payments that become payable post-closing if the practice achieves certain financial or operational milestones, typically revenue growth targets, EMR implementation, EBITDA thresholds, or patient volume metrics. Earnouts serve as a valuation bridge when buyer and seller have different views of the practice’s future earnings potential. They allow buyers to underwrite a higher total transaction value while limiting the risk of overpaying for performance that does not materialize. For sellers, earnouts offer the potential for additional upside but carry meaningful risk, because earnout payments depend on performance outcomes that may be influenced by buyer integration decisions, market dynamics, and operational changes that are partially or fully outside the seller’s control. In healthcare transactions, in particular, earnouts must be carefully structured to avoid creating financial incentives that could implicate federal fraud and abuse laws.
Evaluating Total Economic Value
When evaluating a transaction offer, sophisticated sellers should model the total economic value across all consideration types under multiple scenarios, conservative, base, and optimistic, for both earnout achievement and rollover equity returns. The headline EBITDA multiple is a useful benchmarking tool, but it does not tell the complete story. Two offers with the same headline multiple can have very different economics depending on how consideration is allocated among cash, rollover, and earnout. Your investment banking and legal advisors should help you build this economic model before you make any negotiating decisions.